Ganoderma lucidum polysaccharide inhibits LPS-induced inflammatory injury to mammary epithelial cells

This study sought to investigate whether Ganoderma lucidum polysaccharide (GLP) has a protective effect on lipopolysaccharide (LPS)-induced inflammatory injury to mammary epithelial HC-11 cells and to characterize the mechanism involved. Cell viability was assessed using the cell counting kit 8 (CCK-8) method, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and IL-1 beta levels were measured by enzyme linked immunosorbent assay (ELISA), and I kappa Ba, p65 NF-kappa B and STAT3 mRNA were determined using quantitative reverse transcription PCR (qRT-PCR), p65 and STAT3 protein expression were determined using Western blotting, respectively. GLP was shown to inhibit LPS-induced TNF-alpha, IL-6, and IL-1 beta production (P < 0.01 or P < 0.05), GLP was also shown to increase I kappa B alpha mRNA expression (P < 0.01), decrease p65 and STAT3 mRNA expression (P < 0.01 or P < 0.05), and decrease p-p65, p65, p-STAT3, and STAT3 protein expression in breast epithelial cells (P < 0.01 or P < 0.05). The findings suggest that GLP inhibits nuclear factor kappa-B (NF-kappa B) and signal transducers and activators of transcription (STAT) signaling by preventing I kappa B alpha degradation and p65 and STAT3 phosphorylation. This results in lower LPS-induced TNF-alpha, IL-6, and IL-1 beta production and prevents inflammatory cell injury.(c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.